Dr Lal PathLabs to Acquire 70% Stake in SN Genelab

Dr Lal PathLabs Ltd. has approved the acquisition of a 70% stake in Gujarat-based SN Genelab Pvt. Ltd. (SN Gene) for a cash consideration of up to ₹168 crore. The transaction also includes a performance-linked earn-out capped at ₹31.5 crore. Following completion, SN Gene will become a subsidiary of Dr Lal PathLabs. SN Genelab operates in the diagnostics-genomics segment and provides genomics diagnostic services. Dr Lal PathLabs said the acquisition is intended to strengthen its expertise in genomics and expand its portfolio of advanced diagnostic services. SN Genelab was incorporated in Gujarat in 2013 and reported turnover of ₹57.96 crore in FY26, compared with ₹53.36 crore in FY25 and ₹43.27 crore in FY24. The proposed transaction is not a related-party transaction, according to the company, and no governmental or regulatory approvals are required. The acquisition is expected to be completed by November 30, 2026. The consideration will be funded through cash, with the final earn-out dependent on the agreed performance conditions. The transaction expands Dr Lal PathLabs' presence in specialised diagnostic testing and adds a dedicated genomics business to its existing diagnostic portfolio. My View: The acquisition gives Dr Lal PathLabs an opportunity to expand its specialised genomics offering. The key factor to watch will be how effectively SN Gene's capabilities are integrated into the company's broader diagnostic network.